Feline diabetes care shifts as oral treatment options expand

Feline diabetes treatment is in a transition period, and veterinary media are reflecting that shift. Recent podcast coverage from VETgirl and dvm360 highlights a broader change in clinical thinking: insulin is no longer the only approved treatment path for some cats, and conversations now increasingly center on oral SGLT2 inhibitors, nutrition, remission potential, and the importance of selecting the right patient from day one. (fda.gov)

The backdrop is a rapid regulatory evolution. FDA approved Elanco’s Bexacat, a bexagliflozin tablet, in December 2022 as the first oral treatment for feline diabetes, followed by Boehringer Ingelheim’s Senvelgo, a velagliflozin oral solution, in August 2023. Both are approved to improve glycemic control in otherwise healthy cats with diabetes mellitus that have not previously been treated with insulin. That created a new therapeutic category in feline medicine, but also introduced a more nuanced treatment algorithm than many general practices were used to. (fda.gov)

The newer discussion is not simply “oral drugs versus insulin.” It’s about matching therapy to disease biology and household realities. Recent reviews note that SGLT2 inhibitors can work well in cats with sufficient endogenous insulin production, while recent feline diabetes guidance says remission with these drugs is still not well characterized compared with the longer clinical experience behind insulin-based remission protocols. In parallel, dvm360’s coverage emphasizes that nutrition remains foundational, including palatability, protein content, digestibility, and adjustments for comorbidities, rather than treating food choice as a secondary issue. (pmc.ncbi.nlm.nih.gov)

Safety remains the defining caveat. FDA has warned veterinarians that Bexacat use in insulin-dependent cats, or switching cats off insulin onto Bexacat, is associated with increased risk of diabetic ketoacidosis or euglycemic diabetic ketoacidosis and death. FDA consumer-facing materials make a similar point for both Bexacat and Senvelgo: serious adverse effects, including DKA and pancreatitis, can occur even with screening and monitoring. Senvelgo’s product materials also stress close assessment during the first four weeks after initiation, and UK regulators issued a 2024 safety update after receiving suspected adverse event reports involving DKA. (fda.gov)

Industry and expert commentary has generally been optimistic, but measured. Elanco called Bexacat a first-of-its-kind option at launch, while academic and specialist commentary has described oral SGLT2 inhibitors as potentially practice-changing for newly diagnosed cats, especially where administration burden affects adherence. At the same time, AAHA coverage and recent consensus documents have underscored that these products require careful case selection, upfront diagnostics, and clear communication with the pet parent about red-flag signs such as anorexia, lethargy, vomiting, diarrhea, weakness, and weight loss. (elanco.com)

Why it matters: For veterinarians, this is less about replacing insulin than expanding the decision tree. Oral therapy may improve acceptance for some pet parents and reduce the barrier of twice-daily injections, but it also shifts more weight onto initial workup, ketone assessment, and early follow-up. Practices may need clearer protocols for identifying appropriate newly diagnosed candidates, ruling out prior insulin exposure and concurrent disease, and setting expectations around nutrition, monitoring, and possible transition if glycemic control worsens. The ongoing emphasis on low-carbohydrate feeding and remission support means nutrition conversations remain just as important as drug selection. (fda.gov)

What to watch: The next phase will likely be shaped by post-approval safety surveillance, more real-world data on outcomes and remission, and continued refinement of consensus guidance on when oral SGLT2 inhibitors should be first-line, when insulin remains the better choice, and how early monitoring should be standardized in general practice. (gov.uk)